<DOC>
	<DOCNO>NCT01044498</DOCNO>
	<brief_summary>This open-label , randomize , cross-over study evaluate effect tocilizumab ( TCZ ) pharmacokinetics pharmacodynamics common oral contraceptive ( OC ) female patient active rheumatoid arthritis ( RA ) healthy female volunteer child bear age . The RA patient receive OC combination TCZ , whereas healthy volunteer receive OC . The RA patient receive OC 3 cycle 21 day ; TCZ 8 mg/kg administer intravenous infusion first day Cycle 2 . The healthy volunteer receive OC one 21-day cycle .</brief_summary>
	<brief_title>A Study Tocilizumab Combination With Oral Contraceptive Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Mestranol</mesh_term>
	<criteria>Adult patient child bear potential , 1844 year age . Rheumatoid arthritis ( RA ) 6 month duration . On oral contraceptive without interruption least 3 month normal cycle control . Treatment diseasemodifying anthrheumatic drug ( DMARD ) least 12 week prior study start . Body weight &lt; 150 kg . Functional class IV rheumatoid arthritis ( American College Rheumatology [ ACR ] classification ) . History amenorrhea ( unrelated pregnancy ) . History current inflammatory joint disease RA . Rheumatic autoimmune disease RA .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>